Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Ophthalmic Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533653

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533653

Ophthalmic Drugs

PUBLISHED:
PAGES: 478 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Ophthalmic Drugs Market to Reach US$56.1 Billion by 2030

The global market for Ophthalmic Drugs estimated at US$36.7 Billion in the year 2023, is expected to reach US$56.1 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$34.7 Billion by the end of the analysis period. Growth in the OTC Drugs segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.0 Billion While China is Forecast to Grow at 10.0% CAGR

The Ophthalmic Drugs market in the U.S. is estimated at US$10.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12.0 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Key Trends and Drivers

Ophthalmic drugs play a crucial role in treating a wide range of eye conditions, from infections and inflammations to glaucoma and age-related macular degeneration. These medications include anti-infectives, anti-inflammatories, allergy drops, and drugs for chronic conditions like glaucoma, which are administered as topical drops, ointments, or injections depending on the disease and required effect. Innovation in this field is rapid, with recent developments in drug delivery systems, such as sustained-release implants and in situ forming gels, which improve treatment efficacy by maintaining therapeutic drug levels in the ocular tissues for extended periods.

One of the significant challenges in ophthalmology is drug delivery, as the unique anatomy and protective mechanisms of the eye limit the effectiveness of traditional formulations. Advances in nanotechnology and biodegradable polymers are addressing these challenges by developing systems that can bypass ocular barriers, provide controlled release, and reduce systemic side effects. Moreover, the growing prevalence of diseases such as diabetic retinopathy and age-related macular degeneration drives the need for novel therapeutic agents and delivery systems. There is also an increasing trend towards combination therapies that address multiple pathways involved in complex ocular diseases, improving outcomes and reducing treatment burdens.

The growth in the ophthalmic drugs market is driven by several factors, including the aging global population and increasing prevalence of ocular diseases. Technological advancements in drug delivery systems that enhance drug bioavailability and patient compliance are also significant contributors to market growth. Additionally, the rising demand for more effective treatment options with fewer side effects encourages ongoing research and development. The expansion of this market is further supported by regulatory approvals for new innovative drugs, which are rapidly integrated into clinical practice. Moreover, increased healthcare spending and improved patient awareness about eye health contribute to the growth of the ophthalmic drugs market.

Select Competitors (Total 25 Featured) -

  • AbbVie, Inc.
  • Alcon, Inc.
  • Bausch + Lomb.
  • Bayer AG
  • GSK plc
  • Merck & Co., Inc
  • Nicox SA
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd
  • Senju Pharmaceutical Co., Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.
  • Zhaoke Ophthalmology Pharmaceutical;
Show more
Product Code: MCP27113

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Ophthalmic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Incidence of Eye Diseases Like Glaucoma and AMD
    • Technological Breakthroughs in Targeted Drug Delivery
    • Growth in Demand for Over-the-Counter (OTC) Eye Medications
    • Impact of Diabetes and Other Systemic Diseases on Eye Health
    • Innovations in Biologics for Severe Eye Conditions
    • Regulatory Support for Faster Drug Approval in Ophthalmology
    • Challenges and Opportunities in Dry Eye Syndrome Treatment
    • Advances in Genetics and Personalized Ophthalmic Treatments
    • Global Trends in Healthcare Spending on Vision Care
    • Environmental and Lifestyle Factors Affecting Eye Health
    • Patent Cliffs and the Introduction of Generic Drugs
    • Impact of Patient Compliance on Treatment Outcomes
    • Role of Artificial Intelligence in Predicting Treatment Efficacies
    • R&D Investments and Collaborations in Pharma Industry
    • Awareness Campaigns Targeting Preventative Eye Care
    • Ethical and Regulatory Challenges in Ophthalmic Drug Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ophthalmic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for OTC Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for OTC Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for OTC Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Infection / Inflammation Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Infection / Inflammation Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Infection / Inflammation Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Myopia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Myopia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Myopia Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dry Eye Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dry Eye Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dry Eye Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Uveitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Glaucoma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Glaucoma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Glaucoma Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for FECD Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for FECD Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for FECD Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Allergy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Allergy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Allergy Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Ptosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Ptosis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Ptosis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Retinal Disorder Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Retinal Disorder Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Retinal Disorder Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Local Ocular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Local Ocular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Local Ocular Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Systemic Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Systemic Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: World 16-Year Perspective for Systemic Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: World 16-Year Perspective for Anti-VEGF Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: World 16-Year Perspective for Anti-Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: World 16-Year Perspective for Anti-Inflammatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: World 16-Year Perspective for Anti-Infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: World 16-Year Perspective for Anti-Allergy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 62: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 65: USA Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: USA 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: USA 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: USA 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 74: USA Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: USA Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: USA 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Canada 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Canada 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Canada 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Canada Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Canada 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Japan 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Japan 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Japan 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Japan 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 101: China Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: China 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: China 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: China 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: China 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Ophthalmic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Europe 16-Year Perspective for Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Europe 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Europe 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Europe 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Europe 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 128: France Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: France 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: France 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: France 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: France 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Germany 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Germany 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Germany 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Germany 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Italy 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Italy 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Italy 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Italy 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 164: UK Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: UK 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: UK 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: UK 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 173: UK Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: UK 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Spain 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Spain 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Spain 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 185: Spain Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Spain Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Spain 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Russia 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Russia 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 194: Russia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Russia Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Russia 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 197: Russia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Russia Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Russia 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Europe 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Europe 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Europe Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Europe 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Europe Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Europe 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Ophthalmic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Asia-Pacific Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Asia-Pacific Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Australia 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Australia 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 233: Australia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Australia Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Australia 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 236: Australia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Australia Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Australia 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 239: India Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: India 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: India 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 245: India Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: India Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: India 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 248: India Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: India Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: India 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: South Korea 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: South Korea 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 257: South Korea Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: South Korea Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: South Korea 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 260: South Korea Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: South Korea Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: South Korea 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Rest of Asia-Pacific Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Rest of Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Rest of Asia-Pacific Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Rest of Asia-Pacific 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Ophthalmic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Latin America 16-Year Perspective for Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Latin America 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Latin America 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 284: Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Latin America Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Latin America 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 287: Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Latin America Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Latin America 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Argentina 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Argentina 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 296: Argentina Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Argentina Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Argentina 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 299: Argentina Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Argentina Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Argentina 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Brazil 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Brazil 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 308: Brazil Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Brazil Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Brazil 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 311: Brazil Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Brazil Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Brazil 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 316: Mexico 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 319: Mexico 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 320: Mexico Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Mexico Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 322: Mexico 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 323: Mexico Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Mexico Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 325: Mexico 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 328: Rest of Latin America 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 331: Rest of Latin America 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 333: Rest of Latin America Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 334: Rest of Latin America 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 336: Rest of Latin America Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 337: Rest of Latin America 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Ophthalmic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 340: Middle East 16-Year Perspective for Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 343: Middle East 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 346: Middle East 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 347: Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 348: Middle East Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 349: Middle East 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 350: Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 351: Middle East Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 352: Middle East 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 355: Iran 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 358: Iran 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 359: Iran Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 360: Iran Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 361: Iran 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 362: Iran Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 363: Iran Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 364: Iran 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 367: Israel 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 370: Israel 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 371: Israel Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 372: Israel Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 373: Israel 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 374: Israel Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 375: Israel Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 376: Israel 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 379: Saudi Arabia 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 382: Saudi Arabia 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 384: Saudi Arabia Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 385: Saudi Arabia 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 387: Saudi Arabia Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 388: Saudi Arabia 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 391: UAE 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 394: UAE 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 395: UAE Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 396: UAE Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 397: UAE 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 398: UAE Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 399: UAE Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 400: UAE 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 403: Rest of Middle East 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 406: Rest of Middle East 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
    • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 408: Rest of Middle East Historic Review for Ophthalmic Drugs by Route Of Administration - Topical Administration, Local Ocular Administration and Systemic Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 409: Rest of Middle East 16-Year Perspective for Ophthalmic Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Topical Administration, Local Ocular Administration and Systemic Administration for the Years 2014, 2024 & 2030
    • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 411: Rest of Middle East Historic Review for Ophthalmic Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 412: Rest of Middle East 16-Year Perspective for Ophthalmic Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Infective, Anti-Allergy and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Ophthalmic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Ophthalmic Drugs by Product - Prescription Drugs and OTC Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 415: Africa 16-Year Perspective for Ophthalmic Drugs by Product - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2014, 2024 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Ophthalmic Drugs by Disease Type - Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 418: Africa 16-Year Perspective for Ophthalmic Drugs by Disease Type - Percentage Breakdown of Value Sales for Infection / Inflammation Disease, Myopia Disease, Dry Eye Disease, Uveitis Disease, Glaucoma Disease, FECD Disease, Allergy Disease, Ptosis Disease and Retinal Disorder Disease for the Years 2014, 2024 & 2030
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!